Self-administration of mepolizumab via an autoinjector: the patient experience

Abstract

Introduction: Mepolizumab (Nucala®) is licensed for severe eosinophilic asthma (SEA). A prefilled autoinjector (AI) has been developed to enable in-clinic and at-home, self-administration which may improve the patient treatment experience (PTE). Objectives: Summarise mepolizumab AI PTE Methods: A single-arm, PhIIIa study in SEA evaluated the real-world use of the mepolizumab AI (N=159). Quantitative questionnaires (QQ) were administered to capture the PTE of self-administration. Results: –≥98% patients were able to successfully inject their 3rd dose of mepolizumab using the AI –96% were satisfied/very satisfied with self-administration via the AI at home –96% preferred self-injection at home, compared to in-clinic by a health care professional (HCP) (only patients who previously received mepolizumab administered by a HCP were asked) Conclusions: Nearly all patients successfully self-administered mepolizumab via the AI at week 8 and patient satisfaction using the device at home was high.